2019
DOI: 10.7324/japs.2019.91202
|View full text |Cite
|
Sign up to set email alerts
|

Fucoxanthin enhances 5-FU chemotherapeutic efficacy in colorectal cancer cells by affecting MMP-9 invasive proteins

Abstract: Drug resistance is a major inconvenience which lowers the traditional chemotherapeutic efficacy and is a highly undesirable therapeutic problem which poses particular challenges in the case of colorectal cancer. Fucoxanthin is a natural orange-carotenoid, predominantly found in edible brown algae and justifiably considered as a nutritional ingredient with the capacity to powerfully enhance concurrent drug chemotherapy. It has been well-documented that fucoxanthin has good potential for anti-cancer activity whi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 9 publications
(11 reference statements)
0
1
0
Order By: Relevance
“…and/or enhancers of the existing treatments [22,23]. Currently, there is no clinical evidence of MNP synergy with chemotherapeutic drugs [24][25][26][27] and the studies related to this are mainly based on plant extracts [28][29][30][31][32][33]. Furthermore, few marine-derived drugs (bryostatin-1, panobinostat, plitidepsin, marizomib, and plinabulin) have been successfully evaluated in clinical trials in patients with cancer [34] and specifically in patients with CRC.…”
Section: Introductionmentioning
confidence: 99%
“…and/or enhancers of the existing treatments [22,23]. Currently, there is no clinical evidence of MNP synergy with chemotherapeutic drugs [24][25][26][27] and the studies related to this are mainly based on plant extracts [28][29][30][31][32][33]. Furthermore, few marine-derived drugs (bryostatin-1, panobinostat, plitidepsin, marizomib, and plinabulin) have been successfully evaluated in clinical trials in patients with cancer [34] and specifically in patients with CRC.…”
Section: Introductionmentioning
confidence: 99%